Atherosclerotic Cardiovascular Disease, Heart Failure, and SGLT2 Inhibitors
This SGLT2 inhibitor continuing education course provides timely insights into implementing evidence-based treatment strategies related to atherosclerotic cardiovascular disease, heart failure, and SGLT2 inhibitors. Darren McGuire, MD, MHSc summarizes the glycemic and non-glycemic effects of SGLT2 Inhibitors, their safety profile, and covers recent clinical outcome trials. Cindy Lamendola MSN, ANP-BC, presents case studies that highlight the role of SGLT2 inhibitors in a non-diabetic patient with atherosclerotic cardiovascular disease and heart failure.
Member Cost: $0
Credits: 1.0 CE contact hours, 1.0 CE pharmacology hours
Upon completion of this course, participants will be able to:
- Describe the clinical efficacy and safety profile of SGLT2 inhibitors.
- Interpret CV and heart failure outcomes associated with SGLT2 inhibitors.
- Demonstrate prudent use of SGLT2 inhibitors in clinical practice.
- Darren McGuire, MD, MHSc
- Cindy Lamendola MSN, ANP-BC
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.